Chris Viehbacher takes the helm at Sanofi-Aventis
This article was originally published in Scrip
Chris Viehbacher has taken up his role as Sanofi-Aventis's CEO after leaving GlaxoSmithKlinein September. Mr Viehbacher, who holds German and Canadian nationalities, was previously president of GSK's pharmaceutical operations in North America. He takes over at Sanofi-Aventis from Gerard Le Fur. Mr Viebacher will receive a €2.2 million indemnity and 65,000 consideration-free Sanofi-Aventis shares and 200,000 Sanofi-Aventis stock options in compensation for the benefits that he surrendered after leaving GSK.